The April 1 issue of Cancer Research featured the groundbreaking work done by Harvard Stem Cell Institute (HSCI) researchers at the Dana-Farber Cancer Institute who identified a molecular marker in normal breast tissue that can predict a woman’s risk for developing breast cancer. The study, which was led by Kornelia Polyak of HSCI and Rulla Tamimi of Brigham and Women’s Hospital, examined biopsies from 302 participants who had been diagnosed with benign breast disease. The researchers then compared the tissue of the 69 women who eventually developed cancer in the tissue, with the tissue from the 233 women who did not, to find that women were five times as likely to develop cancer if they had a higher percentage of a particular molecular marker, named Ki67, that identifies proliferating cells.
Dana-Farber Cancer Institute, a client of ALC, is the premier cancer institute in New England, providing compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure and prevention of cancer and related diseases. Founded in 1947, Dana-Farber Cancer Institute is an affiliate of Harvard Medical School.
Read more about their findings here.